Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endothelin-I-mediated vasoconstriction: specific blockade by verapamil.

N S Andrawis1, J Gilligan, D R Abernethy

  • 1Program in Clinical Pharmacology, Brown University School of Medicine, Providence, RI.

Clinical Pharmacology and Therapeutics
|December 1, 1992
PubMed
Summary

This study investigated how three vasodilators reverse endothelin-1 vasoconstriction. Verapamil, unlike isoproterenol and sodium nitroprusside, effectively reversed endothelin-1-induced vasoconstriction, indicating specific antagonism.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tyrosine kinase-targeting drugs-associated heart failure.

British journal of cancer·2017
Same author

The 2030 agenda for sustainable development: a golden opportunity for global violence prevention.

International journal of public health·2016
Same author

GPS for QSP: A Summary of the ACoP6 Symposium on Quantitative Systems Pharmacology and a Stage for Near-Term Efforts in the Field.

CPT: pharmacometrics & systems pharmacology·2016
Same author

Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5.

Clinical pharmacology and therapeutics·2016
Same author

Dose effect of gestational ethanol exposure on placentation and fetal growth.

Placenta·2015
Same author

Application of systems pharmacology to explore mechanisms of hepatotoxicity.

Clinical pharmacology and therapeutics·2014

Area of Science:

  • Cardiovascular Pharmacology
  • Vascular Physiology

Background:

  • Endothelin-1 is a potent vasoconstrictor implicated in various cardiovascular diseases.
  • Understanding vasodilators that can counteract endothelin-1 effects is crucial for therapeutic development.

Purpose of the Study:

  • To compare the capacity of three distinct vasodilators—isoproterenol, sodium nitroprusside, and verapamil—to reverse endothelin-1-mediated vasoconstriction.
  • To elucidate the specific mechanisms by which these vasodilators interact with endothelin-1 pathways.

Main Methods:

  • Brachial artery infusion and forearm strain-gauge plethysmography were employed in 11 healthy male subjects.
  • The study assessed forearm vascular resistance (FVR) changes during infusions of endothelin-1 alone and in combination with isoproterenol, sodium nitroprusside, or verapamil.

Related Experiment Videos

Main Results:

  • Endothelin-1 infusion significantly increased FVR (1.9-fold) in the control state.
  • Isoproterenol and sodium nitroprusside reduced FVR but did not reverse the endothelin-1-induced increase.
  • Verapamil significantly reduced FVR and reversed the endothelin-1-induced vasoconstriction, returning FVR to baseline levels (p < 0.05).

Conclusions:

  • Verapamil acts as a specific antagonist to endothelin-1-mediated vasoconstriction.
  • Isoproterenol and sodium nitroprusside, despite causing vasodilation, do not antagonize the vasoconstrictive effects of endothelin-1.
  • These findings highlight verapamil's potential in managing conditions involving endothelin-1-induced vasoconstriction.